The clinical evidence of the association of glucagon-like peptide-1 receptor agonists with weight loss and cardiovascular risk reduction—particularly among patients without diabetes—suggests these agents may play a meaningful role in managing obesity, diabetes, and cardiometabolic risk more broadly.18 Clinically, this finding underscores the importance of integrating antiobesity medications into routine care, particularly for patients at higher risk of cardiovascular events. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.